Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

MCL1 inhibitor

DRUG CLASS:

MCL1 inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

No biomarker	Chronic Myeloid Leukemia	No biomarker	Chronic Myeloid Leukemia	omacetaxine mepesuccinate Sensitive: A1 - Approval omacetaxine mepesuccinate Sensitive : A1	omacetaxine mepesuccinate Sensitive: A1 - Approval omacetaxine mepesuccinate Sensitive : A1
SS18-SSX fusion	Soft Tissue Sarcoma	SS18-SSX fusion	Soft Tissue Sarcoma	venetoclax + S63845 Sensitive: C3 – Early Trials venetoclax + S63845 Sensitive : C3	venetoclax + S63845 Sensitive: C3 – Early Trials venetoclax + S63845 Sensitive : C3
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	cytarabine + bortezomib + omacetaxine mepesuccinate Sensitive: C3 – Early Trials cytarabine + bortezomib + omacetaxine mepesuccinate Sensitive : C3	cytarabine + bortezomib + omacetaxine mepesuccinate Sensitive: C3 – Early Trials cytarabine + bortezomib + omacetaxine mepesuccinate Sensitive : C3
PRDX1 overexpression	Hepatocellular Cancer	PRDX1 overexpression	Hepatocellular Cancer	AZD5991 Sensitive: C3 – Early Trials AZD5991 Sensitive : C3	AZD5991 Sensitive: C3 – Early Trials AZD5991 Sensitive : C3
BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	S63845 + S55746 Sensitive: D – Preclinical S63845 + S55746 Sensitive : D	S63845 + S55746 Sensitive: D – Preclinical S63845 + S55746 Sensitive : D
MCL1 expression	Multiple Myeloma	MCL1 expression	Multiple Myeloma	APG-3526 Sensitive: D – Preclinical APG-3526 Sensitive : D	APG-3526 Sensitive: D – Preclinical APG-3526 Sensitive : D
BCL2L11 deletion	Diffuse Large B Cell Lymphoma	BCL2L11 deletion	Diffuse Large B Cell Lymphoma	S63845 Resistant: D – Preclinical S63845 Resistant : D	S63845 Resistant: D – Preclinical S63845 Resistant : D
BCL2 expression	Diffuse Large B Cell Lymphoma	BCL2 expression	Diffuse Large B Cell Lymphoma	venetoclax + S63845 Sensitive: D – Preclinical venetoclax + S63845 Sensitive : D	venetoclax + S63845 Sensitive: D – Preclinical venetoclax + S63845 Sensitive : D
MCL1 expression	Diffuse Large B Cell Lymphoma	MCL1 expression	Diffuse Large B Cell Lymphoma	venetoclax + S63845 Sensitive: D – Preclinical venetoclax + S63845 Sensitive : D	venetoclax + S63845 Sensitive: D – Preclinical venetoclax + S63845 Sensitive : D
MCL1 expression	Diffuse Large B Cell Lymphoma	MCL1 expression	Diffuse Large B Cell Lymphoma	S63845 Sensitive: D – Preclinical S63845 Sensitive : D	S63845 Sensitive: D – Preclinical S63845 Sensitive : D
BCL2 expression	Diffuse Large B Cell Lymphoma	BCL2 expression	Diffuse Large B Cell Lymphoma	S63845 Resistant: D – Preclinical S63845 Resistant : D	S63845 Resistant: D – Preclinical S63845 Resistant : D
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	venetoclax + AMG 176 Sensitive: D – Preclinical venetoclax + AMG 176 Sensitive : D	venetoclax + AMG 176 Sensitive: D – Preclinical venetoclax + AMG 176 Sensitive : D